Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 25, 2022

Conditional Survival and Long-Term Efficacy With Nivolumab Plus Ipilimumab vs Sunitinib in Advanced RCC

Cancer

 

Additional Info

Cancer
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer 2022 Apr 05;[EPub Ahead of Print], RJ Motzer, DF McDermott, B Escudier, M Burotto, TK Choueiri, HJ Hammers, P Barthélémy, ER Plimack, C Porta, S George, T Powles, F Donskov, H Gurney, CK Kollmannsberger, MO Grimm, C Barrios, Y Tomita, D Castellano, V Grünwald, BI Rini, MB McHenry, CW Lee, J McCarthy, F Ejzykowicz, NM Tannir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading